Topic:

Partnering

Latest Headlines

Latest Headlines

Amgen link strong as Astellas files with PMDA on Evolocumab, and new indication for Kiklin

Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.

Japan's Meiji Seika ends deal with Amalyte on anti-allergy candidate

Japan's Meiji Seika Pharma has terminated a license deal with U.S.-based Amalyte Pharmaceuticals for its investigational antiallergic drug ME3301 and discontinued development.

Lilly inks a $456M oncology deal with China's Innovent

In a second major bet on Asian R&D, Eli Lilly has signed a $456 million partnership with China's Innovent Biologics to collaborate in oncology, mixing and matching assets with hopes of finding success in each company's home country.

Lilly and China's Innovent Biologics tie up on cancer drug candidates with $56M upfront

Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.

Quintiles taps Google partner Tute Genomics for R&D

Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.

Google's mystery biotech Calico partners with the Broad on aging-related drugs

Slowly but surely, Google's star-driven biotech Calico is laying the foundation for what promises to be a major biotech focused on some of the biggest diseases that limit longevity. There's a Big Pharma partnership with AbbVie, a development deal down in Texas and now it's time to team up with top scientists. Earlier in the week Harvard and MIT's renowned Broad Institute signed on to work with Calico on pushing new therapies into the clinic.

PPD cozies up to trial site group with an eye on enrollment

PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.

Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights

AstraZeneca announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 million.

Catalent shakes up its business with an eye on product launches

Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.

GSK to test Ebola jab with booster from Emergent BioSolutions

GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.